The Economic Architecture of Generic Drug Markets Generic drugs are not simplified copies. They are pharmaceutical products held to the […]

A deep-dive reference on pipeline productivity, attrition economics, open innovation architecture, AI-driven discovery, and patent lifecycle strategy for biopharma decision-makers.

Generic drug development is a high-stakes capital allocation decision disguised as a regulatory exercise. The Abbreviated New Drug Application (ANDA)

Pharmaceutical executives spend billions building patent portfolios. Analysts spend months modeling their worth. And yet the conversation about what actually

A drug patent is not a legal formality. It is the financial architecture that determines whether a company can fund

1. The Problem: Eroom’s Law and the Monolith Trap The Economics Are Getting Worse, Not Better Drug development has gotten

1. The Effective Patent Life Problem: Numbers, Not Theory Here is what the 20-year patent term looks like from inside

Key Takeaways (Executive Summary) Part I: What Drug Repurposing Actually Is — and Why the Economics Changed Defining the Strategy:

Executive Summary The global CDMO market hit USD 238.92 billion in 2024 and is on track to reach USD 465.24